Location: 156 2nd Street, San Francisco, California, United States United States
Founded in: 2015
Stage: Pre-launch
Number of employees: 1-5
Short URL:


Health monitoring revolutionized
San Francisco, California, United States United States
  • About
  • >
  • Activities
  • >
  • News
Company description

Blumio has developed a sensor that can continuously monitor one of our most important vital signs – blood pressure – without requiring an inflatable cuff. Designed for all day wear, Blumio’s novel sensor technology can measure blood pressure noninvasively and continuously, by capturing and analyzing arterial movements in a new way, providing the ability to gain contextual insights into this important biomarker and opening a new window into our understanding of heart health.

  • Catherine Liao
    Catherine Liao | Founder
    I joined my first technology startup at 19, as a systems engineer for one of the first Internet conferencing services in the 90s. Since then, I've held roles ranging from tech ops to tech sales & biz dev to product management & marketing.
  • Oliver Shay
    Oliver Shay | Founder
    Entrepreneurial technologist with a passion for creating solutions that make a positive contribution to people’s lives.
Business model

Blumio's business model consists of one-time hardware sale augmented by a software subscription service. Hardware revenue will be the primary source of revenue, with a gross margin of 60%. On the software side, we intend to have 2 offerings: B2C - a low monthly subscription for advanced analytics and insights for consumers to better manage their condition. B2B - a pay-per-use fee for clinics that want to conduct 24hr BP study as part of hypertension diagnosis. There is already a CPT code in place.

Competitive advantage

Blumio is unique in the use of our proprietary sensing mechanism and the ability to measure blood pressure continuously. Our technology eliminates several variables that affect the performance of our competitors’ devices and for which they must compensate. As a result we anticipate that competing technologies will not be able to meet the accuracy standards laid out by ISO/SP10 and achieve FDA clearance needed to take their products to market.